ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

VXRT Vaxart Inc

0.749
0.00 (0.00%)
Pre Market
Last Updated: 18:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Vaxart Inc VXRT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.749 18:00:00
Open Price Low Price High Price Close Price Previous Close
0.749
more quote information »

Recent News

Date Time Source Heading
30/4/202422:00GLOBEVaxart Announces Positive Results for Its Bivalent Norovirus..
27/3/202423:00GLOBEVaxart to Present at World Vaccine Congress Washington 2024..
20/3/202423:00GLOBEVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing..
15/3/202407:01GLOBEVaxart Provides Business Update and Reports Full Year 2023..
14/3/202422:41IHMARKETNEWSU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil..
08/3/202400:00GLOBEVaxart to Host Full Year 2023 Business Update and Financial..
07/3/202401:23EDGAR2Form 8-K - Current report
07/3/202400:00GLOBEVaxart, Inc. Appoints Steven Lo as President, Chief..
01/3/202408:30EDGAR2Form 8-K - Current report
16/2/202408:10EDGAR2Form 8-K - Current report
14/2/202409:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202400:00GLOBEVaxart Announces Publication in Vaccines of Non-Human..
03/2/202408:49EDGAR2Form 8-K/A - Current report: [Amend]
20/1/202409:14EDGAR2Form 8-K - Current report
20/1/202408:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
20/1/202400:30GLOBEVaxart Receives $9.27 Million BARDA Project NextGen Award to..
17/1/202409:18EDGAR2Form 8-K - Current report
17/1/202401:25GLOBEVaxart Announces $10.0 Million Registered Direct Offering..
17/1/202401:22GLOBEVaxart, Inc. Announces Management Change
17/1/202401:19EDGAR2Form 8-K - Current report
22/12/202300:00GLOBEVaxart Announces Last Subject Dosed in Phase 1 Trial of Its..
03/11/202307:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202307:11EDGAR2Form 8-K - Current report
03/11/202307:01GLOBEVaxart Provides Business Update and Reports Third Quarter..
02/11/202323:00GLOBEVaxart Doses First Subject in Phase 1 Trial of Its Norovirus..
26/10/202323:00GLOBEVaxart to Host Third Quarter 2023 Business Update and..
24/10/202308:09EDGAR2Form 8-K/A - Current report: [Amend]
24/10/202308:01EDGAR2Form 8-K - Current report
11/10/202323:00GLOBEVaxart to Present at World Vaccine Congress Europe 2023 on..
21/9/202322:00GLOBEVaxart to Participate in Fireside Chat at 2023 Cantor Global..
07/9/202306:43EDGAR2Form 8-K - Current report
07/9/202306:05GLOBEVaxart Announces Topline Data from the Phase 2 Challenge..
04/8/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202306:20EDGAR2Form 8-K - Current report
04/8/202306:01GLOBEVaxart Provides Business Update and Reports Second Quarter..
02/8/202311:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202311:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202311:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202311:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202310:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/7/202322:00GLOBEVaxart to Host Second Quarter 2023 Business Update and..
27/7/202306:20EDGAR2Form 8-K - Current report
11/7/202306:12EDGAR2Form 8-K - Current report
06/7/202322:00GLOBEVaxart Announces Positive Preliminary Topline Data from..
29/6/202306:22EDGAR2Form 8-K - Current report
27/6/202306:45GLOBEVaxart Stockholders Approve All Four Proposals in the 2023..
22/6/202306:30GLOBEVaxart Encourages All Stockholders of Record as of April 28,..
07/6/202323:16GLOBEVaxart, Inc. Announces Pricing of $15,000,000 Public..
07/6/202306:01GLOBEVaxart, Inc. Announces Proposed Public Offering of Common..
06/6/202322:00GLOBEVaxart Announces Last Subject Dosed in Phase 2 Trial of its..

Your Recent History

Delayed Upgrade Clock